Bendamustine-Bortezomib-Dexametasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma: A Real-Life Experience

Bendamustine is a bifunctional alkylating agent, with low toxicity, proved to be effective in relapsed, refractory (rr) and in newly-diagnosed Multiple Myeloma (MM).

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Claudio Cerchione, Lucio Catalano, Anna Emanuele Pareto, Santina Basile, Luana Marano, Ilaria Peluso, Luigia Simeone, Orsola Vitagliano, Salvatore Palmieri, Stefano Rocco, Alessandra Romano, Felicetto Ferrara, Fabrizio Pane Source Type: research